Search

Your search keyword '"Masciale, Valentina"' showing total 49 results
Start Over Author "Masciale, Valentina" Publication Year Range Last 10 years
49 results on '"Masciale, Valentina"'

2. Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma

Author

Grisendi, Giulia, Dall’Ora, Massimiliano, Casari, Giulia, Spattini, Giliola, Farshchian, Moein, Melandri, Aurora, Masciale, Valentina, Lepore, Fabio, Banchelli, Federico, Costantini, Riccardo Cuoghi, D’Esposito, Angela, Chiavelli, Chiara, Spano, Carlotta, Spallanzani, Andrea, Petrachi, Tiziana, Veronesi, Elena, Ferracin, Manuela, Roncarati, Roberta, Vinet, Jonathan, Magistri, Paolo, Catellani, Barbara, Candini, Olivia, Marra, Caterina, Eccher, Albino, Bonetti, Luca Reggiani, Horwitz, Edwin M., Di Benedetto, Fabrizio, and Dominici, Massimo

Published
2024
Full Text
View/download PDF

6. Metabolically activated and highly polyfunctional intratumoral VISTA+ regulatory B cells are associated with tumor recurrence in early stage NSCLC.

Author

Tartaro, Domenico Lo, primary, Aramini, Beatrice, additional, Masciale, Valentina, additional, Paschalidis, Nikolaos, additional, Lofaro, Francesco Demetrio, additional, Neroni, Anita, additional, Borella, Rebecca, additional, Santacroce, Elena, additional, Ciobanu, Alin Liviu, additional, Samarelli, Anna Valeria, additional, Boraldi, Federica, additional, Quaglino, Daniela, additional, Dubini, Alessandra, additional, Gaudio, Michele, additional, Manzotti, Gloria, additional, Reggiani, Francesca, additional, Torricelli, Federica, additional, Ciarrocchi, Alessia, additional, Neri, Antonino, additional, Bertolini, Federica, additional, Dominici, Massimo, additional, Filosso, Pier Luigi, additional, Stella, Franco, additional, Gibellini, Lara, additional, De Biasi, Sara, additional, and Cossarizza, Andrea, additional

Published
2024
Full Text
View/download PDF

7. Proteomic profiling of formalin-fixed paraffine-embedded tissue reveals key proteins related to lung dysfunction in idiopathic pulmonary fibrosis

Author

Samarelli, Anna Valeria, primary, Tonelli, Roberto, additional, Raineri, Giulia, additional, Bruzzi, Giulia, additional, Andrisani, Dario, additional, Gozzi, Filippo, additional, Marchioni, Alessandro, additional, Costantini, Matteo, additional, Fabbiani, Luca, additional, Genovese, Filippo, additional, Pinetti, Diego, additional, Manicardi, Linda, additional, Castaniere, Ivana, additional, Masciale, Valentina, additional, Aramini, Beatrice, additional, Tabbì, Luca, additional, Rizzato, Simone, additional, Bettelli, Stefania, additional, Manfredini, Samantha, additional, Dominici, Massimo, additional, Clini, Enrico, additional, and Cerri, Stefania, additional

Published
2024
Full Text
View/download PDF

9. Expression of HOXB7 in the Lung of Patients with Idiopathic Pulmonary Fibrosis: A Proof-of-Concept Study.

Author

Samarelli, Anna Valeria, Tonelli, Roberto, Raineri, Giulia, Mastrolia, Ilenia, Costantini, Matteo, Fabbiani, Luca, Catani, Virginia, Petrachi, Tiziana, Bruzzi, Giulia, Andrisani, Dario, Gozzi, Filippo, Marchioni, Alessandro, Masciale, Valentina, Aramini, Beatrice, Ruggieri, Valentina, Grisendi, Giulia, Dominici, Massimo, Cerri, Stefania, and Clini, Enrico

Subjects
LUNGS, PULMONARY fibrosis, IDIOPATHIC pulmonary fibrosis, PROOF of concept, GENE families, LUNG cancer, INTERSTITIAL lung diseases
Abstract

Background: The molecular pathways involved in the onset and progression of idiopathic pulmonary fibrosis (IPF) still need to be fully clarified as some are shared with lung cancer development. HOXB7, a member of the homeobox (Hox) gene family, has been found involved in various cancers. Methods: Immunohistochemical (IHC) analysis was run on lung tissue samples from surgical lung biopsy (SLB) of 19 patients with IPF, retrospectively selected from the IPF database of the University Hospital of Modena. HOXB7 expression was analyzed and compared with that of five patients with no evidence of pulmonary fibrosis as controls. Results: The semi-quantitative analysis of IHC showed that HOXB7 protein expression was higher in IPF patients compared to controls (difference between means = 6.2 ± 2.37, p = 0.0157). Further, HOXB7 expression was higher in IPF patients with a higher extent of fibrosis (50–75%)—measured with high-resolution computer tomography—compared to those with a lower extent (0–25%) (difference between means = 25.74 ± 6.72, p = 0.004). Conclusions: The expression of HOXB7 is higher in the lung of IPF patients compared to controls, and was represented in different cellular compartments within the lung niche. Further investigations are needed to clarify its role in the pathogenesis and progression of IPF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Cancer stem cells and their microenvironment

Author

Masciale, Valentina, primary, Grisendi, Giulia, additional, Banchelli, Federico, additional, D’Amico, Roberto, additional, Morandi, Uliano, additional, Dominici, Massimo, additional, Haider, Khawaja Husnain, additional, and Aramini, Beatrice, additional

Published
2020
Full Text
View/download PDF

13. Chasing the Role of miRNAs in RCC: From Free-Circulating to Extracellular-Vesicle-Derived Biomarkers

Author

Mastrolia, Ilenia, primary, Catani, Virginia, additional, Oltrecolli, Marco, additional, Pipitone, Stefania, additional, Vitale, Maria Giuseppa, additional, Masciale, Valentina, additional, Chiavelli, Chiara, additional, Bortolotti, Carlo Augusto, additional, Nasso, Cecilia, additional, Grisendi, Giulia, additional, Sabbatini, Roberto, additional, and Dominici, Massimo, additional

Published
2023
Full Text
View/download PDF

14. Impact of soluble tumor necrosis factor-related apoptosis-inducing ligand released by engineered adipose mesenchymal stromal cells on white blood cells

Author

Casari, Giulia, primary, Dall'Ora, Massimiliano, additional, Melandri, Aurora, additional, Masciale, Valentina, additional, Chiavelli, Chiara, additional, Prapa, Malvina, additional, Neri, Giovanni, additional, Spano, Maria Carlotta, additional, Murgia, Alba, additional, D'Esposito, Angela, additional, Baschieri, Maria Cristina, additional, Ceccherelli, Giovanni Battista, additional, Dominici, Massimo, additional, and Grisendi, Giulia, additional

Published
2023
Full Text
View/download PDF

15. Chasing Circulating Biomarkers in Renal Cell Carcinoma: the Case of Extracellular Vesicles and their miRNA Cargos

Author

Mastrolia, Ilenia, primary, Catani, Virginia, additional, Oltrecolli, Marco, additional, Pipitone, Stefania, additional, Vitale, Maria Giuseppa, additional, Masciale, Valentina, additional, Chiavelli, Chiara, additional, Bortolotti, Carlo Augusto, additional, Nasso, Cecilia, additional, Grisendi, Giulia, additional, Sabbatini, Roberto, additional, and Dominici, Massimo, additional

Published
2023
Full Text
View/download PDF

22. Phenotypic, functional, and metabolic heterogeneity of immune cells infiltrating non–small cell lung cancer

Author

Aramini, Beatrice, primary, Masciale, Valentina, additional, Samarelli, Anna Valeria, additional, Dubini, Alessandra, additional, Gaudio, Michele, additional, Stella, Franco, additional, Morandi, Uliano, additional, Dominici, Massimo, additional, De Biasi, Sara, additional, Gibellini, Lara, additional, and Cossarizza, Andrea, additional

Published
2022
Full Text
View/download PDF

23. Cancer Stem Cells and Cell Cycle Genes as Independent Predictors of Relapse in Non-small Cell Lung Cancer: Secondary Analysis of a Prospective Study

Author

Masciale, Valentina, primary, Banchelli, Federico, additional, Grisendi, Giulia, additional, D’Amico, Roberto, additional, Maiorana, Antonino, additional, Stefani, Alessandro, additional, Morandi, Uliano, additional, Stella, Franco, additional, Dominici, Massimo, additional, and Aramini, Beatrice, additional

Published
2022
Full Text
View/download PDF

25. The Influence of Cancer Stem Cells on the Risk of Relapse in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Prospective Cohort Study

Author

Masciale, Valentina, primary, Banchelli, Federico, additional, Grisendi, Giulia, additional, D’Amico, Roberto, additional, Maiorana, Antonino, additional, Stefani, Alessandro, additional, Morandi, Uliano, additional, Stella, Franco, additional, Dominici, Massimo, additional, and Aramini, Beatrice, additional

Published
2022
Full Text
View/download PDF

27. Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development

Author

Samarelli, Anna Valeria, Masciale, Valentina, Aramini, Beatrice, Coló, Georgina Pamela, Tonelli, Roberto, Marchioni, Alessandro, Bruzzi, Giulia, Gozzi, Filippo, Andrisani, Dario, Castaniere, Ivana, Manicardi, Linda, Moretti, Antonio, Tabbì, Luca, Guaitoli, Giorgia, Cerri, Stefania, Dominici, Massimo, and Clini, Enrico

Subjects
Lung Neoplasms, cancer associated fibroblasts (CAFs), QH301-705.5, CAFs, Review, respiratory system, idiopathic pulmonary fibrosis, lung cancer, myofibroblast, mechanotrasduction, Mechanotransduction, Cellular, respiratory tract diseases, Transforming Growth Factor beta1, Chemistry, Animals, Humans, Biology (General), Myofibroblasts, QD1-999
Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung disease (ILD) of unknown aetiology, with a median survival of 2-4 years from the time of diagnosis. Although IPF has unknown aetiology by definition, there have been identified several risks factors increasing the probability of the onset and progression of the disease in IPF patients such as cigarette smoking and environmental risk factors associated with domestic and occupational exposure. Among them, cigarette smoking together with concomitant emphysema might predispose IPF patients to lung cancer (LC), mostly to non-small cell lung cancer (NSCLC), increasing the risk of lung cancer development. To this purpose, IPF and LC share several cellular and molecular processes driving the progression of both pathologies such as fibroblast transition proliferation and activation, endoplasmic reticulum stress, oxidative stress, and many genetic and epigenetic markers that predispose IPF patients to LC development. Nintedanib, a tyrosine-kinase inhibitor, was firstly developed as an anticancer drug and then recognized as an anti-fibrotic agent based on the common target molecular pathway. In this review our aim is to describe the updated studies on common cellular and molecular mechanisms between IPF and lung cancer, knowledge of which might help to find novel therapeutic targets for this disease combination.

Published
2021

28. Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations

Author

Guaitoli, Giorgia, primary, Bertolini, Federica, additional, Bettelli, Stefania, additional, Manfredini, Samantha, additional, Maur, Michela, additional, Trudu, Lucia, additional, Aramini, Beatrice, additional, Masciale, Valentina, additional, Grisendi, Giulia, additional, Dominici, Massimo, additional, and Barbieri, Fausto, additional

Published
2021
Full Text
View/download PDF

29. Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature

Author

Isca, Chrystel, primary, Piacentini, Federico, additional, Mastrolia, Ilenia, additional, Masciale, Valentina, additional, Caggia, Federica, additional, Toss, Angela, additional, Piombino, Claudia, additional, Moscetti, Luca, additional, Barbolini, Monica, additional, Maur, Michela, additional, Dominici, Massimo, additional, and Omarini, Claudia, additional

Published
2021
Full Text
View/download PDF

30. Use of Octreotide in association with talc poudrage for the management of a severe chylothorax: A case report

Author

Lovati, Eleonora, Ruggiero, Ciro, Masciale, Valentina, Stefani, Alessandro, Morandi, Uliano, Aramini, Beatrice, Eleonora Lovati, Ciro Ruggiero, Valentina Masciale, Alessandro Stefani, Uliano Morandi, and Beatrice Aramini

Subjects
Case report, Octreotide, talc poudrage, management, chylothorax, Surgery, Octreotide, Chylothorax, Conservative treatment, Talc poudrage
Abstract

Highlights • Chylothorax is an uncommon form of benign pleural effusion. • It may have poor prognosis if not properly treated. • Conservative measures are the first line of treatment for managing chylothorax. • Surgery is considered an option for recurrent chylothorax. • In our recurrent case, octreotide plus talc poudrage was effective., Introduction and importance Chylothorax is an uncommon form of pleural effusion characterized by the presence of chylomicrons, triglycerides and cholesterol in the physical and chemical examination of the pleural fluid. It may have poor prognosis if not properly treated. Currently, conservative measures are the first line of treatment for managing chylothorax. The aim of our study is to show and suggest the use of octreotide in association with talc poudrage as good option to manage post-operative a severe chylothorax. Case presentation A 59-year-old male patient who underwent a replacement of the ascending aorta, aortic hemiarch and surgery of the aortic valve for aortic dissection showed a severe pleural effusion three months after surgery. Because the physical and chemical examination of the pleural fluid revealed high levels of triglycerides and cholesterol, a conservative treatment with pleural drainage, TPN and nihil per os was attempted, with the introduction of 0.3 mg/die of octreotide on day thirty-four. With the application of talc poudrage, the chylothorax completely resolved. Clinical discussion Octreotide has been shown to significantly decrease chylous effusion in many studies, but the dose and duration of therapy have not yet been defined. Our patient responded partially to octreotide after two days of treatment, with the drainage leak reduced to less than 100 mL/day. Conclusion After octreotide treatment associated with talc poudrage, the drainage leak was drastically reduced, suggesting that this could be a useful approach in the management of severe chylous leaks.

Published
2021

31. Cancer stem cells and macrophages: molecular connections and future perspectives against cancer

Author

Aramini, Beatrice, Masciale, Valentina, Grisendi, Giulia, Banchelli, Federico, D'Amico, Roberto, Maiorana, Antonino, Morandi, Uliano, Dominici, Massimo, Khawaja Husnain Haider, Beatrice Aramini, Valentina Masciale, Giulia Grisendi, Federico Banchelli, Roberto D’Amico, Antonino Maiorana, Uliano Morandi, Massimo Dominici, and Khawaja Husnain Haider

Subjects
cancer stem cells, future perspectives, Cancer stem cells, Macrophage, Macrophages, Cancer stem cell, Cancer, Future perspectives, Target treatments, Review, macrophages, Future perspective
Abstract

Cancer stem cells (CSCs) have been considered the key drivers of cancer initiation and progression due to their unlimited self-renewal capacity and their ability to induce tumor formation. Macrophages, particularly tumor-associated macrophages (TAMs), establish a tumor microenvironment to protect and induce CSCs development and dissemination. Many studies in the past decade have been performed to understand the molecular mediators of CSCs and TAMs, and several studies have elucidated the complex crosstalk that occurs between these two cell types. The aim of this review is to define the complex crosstalk between these two cell types and to highlight potential future anti-cancer strategies.

Published
2021

38. Arming Mesenchymal Stromal/Stem Cells Against Cancer: Has the Time Come?

Author

Golinelli, Giulia, primary, Mastrolia, Ilenia, additional, Aramini, Beatrice, additional, Masciale, Valentina, additional, Pinelli, Massimo, additional, Pacchioni, Lucrezia, additional, Casari, Giulia, additional, Dall’Ora, Massimiliano, additional, Soares, Milena Botelho Pereira, additional, Damasceno, Patrícia Kauanna Fonseca, additional, Silva, Daniela Nascimento, additional, Dominici, Massimo, additional, and Grisendi, Giulia, additional

Published
2020
Full Text
View/download PDF

42. CD44+/EPCAM+ cells detect a subpopulation of ALDHhigh cells in human non-small cell lung cancer: A chance for targeting cancer stem cells?

Author

Masciale, Valentina, primary, Grisendi, Giulia, additional, Banchelli, Federico, additional, D’Amico, Roberto, additional, Maiorana, Antonino, additional, Sighinolfi, Pamela, additional, Stefani, Alessandro, additional, Morandi, Uliano, additional, Dominici, Massimo, additional, and Aramini, Beatrice, additional

Published
2020
Full Text
View/download PDF

43. Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study

Author

Aramini, Beatrice, primary, Banchelli, Federico, additional, Bettelli, Stefania, additional, Manfredini, Samantha, additional, D’Amico, Roberto, additional, Masciale, Valentina, additional, Pinelli, Massimo, additional, Moretti, Margherita, additional, Stefani, Alessandro, additional, Bertolini, Federica, additional, Dominici, Massimo, additional, Morandi, Uliano, additional, and Maiorana, Antonino, additional

Published
2020
Full Text
View/download PDF

46. Correlating tumor-infiltrating lymphocytes and lung cancer stem cells: a cross-sectional study

Author

Masciale, Valentina, primary, Grisendi, Giulia, additional, Banchelli, Federico, additional, D’Amico, Roberto, additional, Maiorana, Antonino, additional, Sighinolfi, Pamela, additional, Pinelli, Massimo, additional, Lovati, Eleonora, additional, Stefani, Alessandro, additional, Morandi, Uliano, additional, Dominici, Massimo, additional, and Aramini, Beatrice, additional

Published
2019
Full Text
View/download PDF

47. Challenging the efficacy of checkpoint inhibitors: a new 3D model for a precision medicine approach

Author

Elisabetta Manuela Foppiani, Olivia Candini, Beatrice Aramini, MASCIALE, VALENTINA, Giulia Grisendi, Matteo Brogli, Giorgio Mari, Massimo Dominici., Elisabetta Manuela Foppiani, Olivia Candini, Beatrice Aramini, MASCIALE, VALENTINA, Giulia Grisendi, Matteo Brogli, Giorgio Mari, and Massimo Dominici.

Subjects
Checkpoint inhibitors, 3D model, precision medicine approach, biological phenomena, cell phenomena, and immunity
Abstract

Challenging the efficacy of checkpoint inhibitors: a new 3D model for a precision medicine approach.

Published
2018

48. Precision Medicine in Lung Cancer : Challenges and Opportunities in Diagnostic and Therapeutic Purposes

Author

Aramini, Beatrice, Haider, Khawaja Husnain, Dominici, Massimo, D´Amico, Roberto, Banchelli, Federico, and Masciale, Valentina

Subjects
Medical
Abstract

Lung cancer is one of the leading causes of cancer death among both men and women, making up almost 25% of all cancer deaths. Precision medicine shows promise for improving many aspects of health and healthcare, including tests, drugs, and other technologies that support innovation, with the possibility of new partnerships with scientists in a wide range of specialties. Non–small-cell lung cancer (NSCLC) has become a prominent example of the success of precision medicine in treating solid tumor malignancies. The first step in this process involves new blood-based diagnostics, which can now noninvasively provide clinically useful information. However, the identification of novel biomarkers that could be used in early diagnosis is urgently needed, especially for guiding initial therapy and predicting relapse or drug resistance following the administration of novel targeted therapies.

Published
2019

49. CD44+/EPCAM+ cells detect a subpopulation of ALDH high cells in human non-small cell lung cancer: A chance for targeting cancer stem cells?

Author

Masciale V, Grisendi G, Banchelli F, D'Amico R, Maiorana A, Sighinolfi P, Stefani A, Morandi U, Dominici M, and Aramini B

Abstract

Objectives: Several studies demonstrated that aldehyde dehydrogenase (ALDH) and CD44 are the most considered cancer stem cells (CSC) markers. However, a comparison between ALDH high cells and CD44+ cells have been previously described with no significant correlation. Indeed, the aim of the present research is to identify a superficial marker able to match with ALDH high cells population in freshly isolated human lung cancer cells., Materials and Methods: This cross-sectional study analyzed the expression of ALDH high/low cells and the positivity for CD44 and epithelium cell adhesion molecule (EPCAM) antigens in surgical lung cancer tissues. The main approach was a cytofluorimetric analysis of ALDH expression and positivity for CD44/EPCAM on primary cell population obtained from 23 patients harboring NSCLC., Results: There was a highly positive correlation between the expressions of ALDH high and CD44+/EPCAM+ cells, with a Pearson's correlation coefficient equal to 0.69 (95% CI 0.39-0.86; P = 0.0002), and Spearman's correlation coefficient equal to 0.52 ( P = 0.0124). The average paired difference between the expression of ALDH high and CD44+/EPCAM+ cells was very close to 0, being 0.1% (SD 2.5%); there was no difference between these subpopulations in terms of means (95% CI = -1.0; 1.2%, P = 0.8464). These results highlight a strong similarity between ALDH high and CD44+/EPCAM+ cells., Conclusions: Our study is the first attempt which identifies a high correlation between the ALDH high and the CD44+/EPCAM+ cells, thus suggesting the possibility to use this superficial marker for future target treatments against lung cancer stem cells., Competing Interests: CONFLICTS OF INTEREST None of the Authors have any competing interests.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results